In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Biocept (BIOC - Research Report), with a price target of $4.00. The company's shares closed yesterday at $0.80.According to TipRanks, McCarthy is an analyst with an average return of -38.8% and a 14.29% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Immutep, Actinium Pharmaceuticals, and Daré Bioscience.The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Biocept with a $7.50 average price target.See the top stocks recommended by analysts >>The company has a one-year high of $4.40 and a one-year low of $0.70.
https://www.tipranks.com/news/blurbs/maxim-group-remains-a-buy-on-biocept-bioc?utm_source=advfn.com&utm_medium=referral
Biocept (NASDAQ:BIOC)
Gráfico Histórico do Ativo
De Jan 2023 até Fev 2023 Click aqui para mais gráficos Biocept.
Biocept (NASDAQ:BIOC)
Gráfico Histórico do Ativo
De Fev 2022 até Fev 2023 Click aqui para mais gráficos Biocept.